Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LKA651 in Diabetic Macular Edema
NCT03927690Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2019
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of LKA651 in diabetic macular edema (DME) (3 arms), sponsored by Novartis. Primary endpoints: Number of Participants With Adverse Events up to 24 weeks, Number of Participants With Ocular Adverse Events by Preferred Term in Study Eye up to 24 weeks and 7 more. Started May 2019; status: completed.
02
Drugs
LKA651
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03927690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927690.